misonidazole has been researched along with Cancer of Prostate in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchegger, F; De Perrot, T; Garibotto, V; Mainta, IC; Miralbell, R; Tille, JC; Vallée, JP; Zilli, T | 1 |
| Campion, L; Chèze-Le-Rest, C; Delpon, G; Dore, M; Ferrer, L; Guerif, S; Hatt, M; Kandel-Aznar, C; Meingan, P; Paris, F; Potiron, V; Rousseau, C; Supiot, S; Visvikis, D | 1 |
| Ai, H; Chen, S; Cheng, Z; Jiang, X; Li, X; Lu, H; Qing, H; Wei, R; Wu, C; Xu, G | 1 |
| Ackerstaff, E; Carlin, S; Cho, H; Humm, JL; Koutcher, JA; Ling, CC; Lupu, ME; O'Donoghue, J; Rizwan, A; Wang, Y; Zanzonico, PB | 1 |
| Brown, JM; Carlson, DJ; Chen, ZJ; Keall, PJ; Loo, BW | 1 |
| Campa, J; Finn, R; Forster, G; Humm, J; Larson, S; Ling, C; Polycarpe-Holman, D; Zanzonico, P | 1 |
| Franko, AJ; Koch, CJ | 1 |
| Hall, EJ; Olsson, CA; Romas, NA; Tomashefsky, P; White, RD | 1 |
| Evans, ML; Graham, MM; Koh, WJ; Krohn, KA; Lewellen, TK; Peterson, LM; Rasey, JS | 1 |
| Allen, PS; Arnfield, M; Chapman, JD; Chetner, MP; McPhee, MS; Meeker, BE; Soderlind, K; Stobbe, CC; Trimble, L; Walz, N | 1 |
| Henry, JM; Isaacs, JT | 1 |
| Franko, AJ; Garrecht, BM; Hughes, D; Koch, CJ; Sharplin, J | 1 |
| Arnfield, MR; Chapman, JD; Gonzalez, S; Lakey, WH; McPhee, MS; Meeker, BE; Tulip, J | 1 |
| Chapman, JD; Lakey, WH; McPhee, MS; Meeker, BE; Thomas, G; Thorndyke, C | 1 |
| Brailovsky, CA; Corcos, J; Elhilali, MM; Fathi, MA; Fisher, GJ; Nigam, VN; Pageau, R; Tahan, TW | 1 |
15 other study(ies) available for misonidazole and Cancer of Prostate
| Article | Year |
|---|---|
The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
Topics: Aged; Androgen Antagonists; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Positron-Emission Tomography; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Tumor Hypoxia | 2018 |
Reoxygenation during radiotherapy in intermediate-risk prostate cancer.
Topics: Cell Hypoxia; Fluorine Radioisotopes; Humans; Male; Middle Aged; Misonidazole; Oxygen; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2019 |
Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Male; Mice; Mice, Nude; Misonidazole; Multimodal Imaging; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
Topics: Animals; Autoradiography; Cell Hypoxia; Disease Models, Animal; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Misonidazole; Nitroimidazoles; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Rats | 2009 |
Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.
Topics: Algorithms; Capillaries; Cell Hypoxia; Cell Survival; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Linear Models; Male; Misonidazole; Oxygen Consumption; Partial Pressure; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Treatment Failure | 2011 |
Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors.
Topics: Animals; Carcinoma, Squamous Cell; Equipment Design; Equipment Failure Analysis; Fluorodeoxyglucose F18; Humans; Male; Misonidazole; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Rats; Reproducibility of Results; Restraint, Physical; Sensitivity and Specificity; Species Specificity; Subtraction Technique | 2006 |
Binding of misonidazole to V79 spheroids and fragments of Dunning rat prostatic and human colon carcinomas in vitro: diffusion of oxygen and reactive metabolites.
Topics: Animals; Carbon Radioisotopes; Cells, Cultured; Colonic Neoplasms; Cricetinae; Cricetulus; Diffusion; Humans; In Vitro Techniques; Male; Misonidazole; Models, Biological; Nitroimidazoles; Oxygen; Prostatic Neoplasms; Rats; Tritium | 1984 |
Misonidazole as a chemosensitizer in the treatment of the Dunning prostate cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cyclophosphamide; Dose-Response Relationship, Drug; Leukocyte Count; Male; Misonidazole; Neoplasm Staging; Prostatic Neoplasms; Rats; Statistics as Topic; Time Factors | 1984 |
Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Fluorine Radioisotopes; Humans; Lung Neoplasms; Male; Misonidazole; Neoplasms; Prostatic Neoplasms; Tomography, Emission-Computed | 1996 |
Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors.
Topics: Adenosine Triphosphate; Animals; Cell Hypoxia; Female; Ischemia; Magnetic Resonance Spectroscopy; Male; Misonidazole; Photochemotherapy; Prostatic Neoplasms; Rats; Rats, Inbred Strains | 1991 |
Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Male; Misonidazole; Photochemotherapy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Rats; Tumor Stem Cell Assay | 1989 |
Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Humans; Hypoxia; Male; Mice; Mice, Inbred BALB C; Misonidazole; Oxygen; Prostatic Neoplasms | 1987 |
Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole.
Topics: Animals; Combined Modality Therapy; Female; Male; Misonidazole; Oxygen; Photochemotherapy; Prostatic Neoplasms; Rats; Rats, Inbred Strains; Temperature | 1986 |
The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas.
Topics: Adenocarcinoma; Animals; Cell Survival; Cesium Radioisotopes; Gamma Rays; Kinetics; Male; Misonidazole; Neoplasm Transplantation; Oxygen; Prostatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Rats | 1985 |
Combination of 60Co gamma-radiation, misonidazole, and maltose tetrapalmitate in the treatment of Dunning prostatic tumor in the rat.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cobalt Radioisotopes; Combined Modality Therapy; Glycolipids; Male; Misonidazole; Nitroimidazoles; Prostatic Neoplasms; Rats | 1985 |